Amgen Reports In-Favor Uphold of its Two Patents for Repatha from Delaware Jury

 Amgen Reports In-Favor Uphold of its Two Patents for Repatha from Delaware Jury

Amgen Reports In-Favor Uphold of its Two Patents for Repatha from Delaware Jury

Shots:

  • Amgen receives in-favor upholding validity for Repatha from Delaware Jury, with two out of five asserted claims based on its patents meeting the legal requirements of written description and enablement
  • In Mar,2016 Sanofi and Regeneron admitted infringement of Amgen’s patents, regaining Amgen with two patents of Repatha but was overturned on appeal in the US District Court for the District of Delaware
  • Sanofi and Regeneron plans to file appeal to the Court of Appeals, in addition to the District Court for overturning the jury’s verdict with the onset of new trial 
  • Repatha (evolocumab) is mAb inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) and is approved in 60 countries including the US, Japan, Canada & EU

Click here to read full press release/ article | Ref: Amgen | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post